Quarterly report pursuant to Section 13 or 15(d)

Acquisitions - Narrative (Details)

v3.22.2.2
Acquisitions - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended
Jul. 01, 2022
Sep. 30, 2022
Payments to Acquire Businesses, Net of Cash Acquired, Total   $ 101,184
Namocell Inc    
Business Combination, Consideration Transferred, Total   111,784
Maximum contingent consideration $ 25,000 25,000
Payments to Acquire Businesses, Net of Cash Acquired, Total $ 101,200 101,184
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual   2,400
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual   700
Namocell Inc | Developed Technology Rights [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 13 years  
Namocell Inc | Customer Relationships [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 4 years  
Namocell Inc | Noncompete Agreements [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 3 years  
Acquisition of Asuragen, Inc. [Member]    
Maximum contingent consideration   $ 105,000